The cost saving opportunity of introducing a card review into measles-containing vaccination campaigns.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
24 09 2019
Historique:
received: 19 02 2019
revised: 12 08 2019
accepted: 13 08 2019
pubmed: 1 9 2019
medline: 29 9 2020
entrez: 1 9 2019
Statut: ppublish

Résumé

Measles vaccination is a cost-effective way to prevent infection and reduce mortality and morbidity. However, in countries with fragile routine immunization infrastructure, coverage rates are still low and supplementary immunization campaigns (SIAs) are used to reach previously unvaccinated children. During campaigns, vaccine is generally administered to every child, regardless of their vaccination status and as a result, there is the possibility that a child that is already immune to measles (i.e. who has had 2+ vaccinations) would receive an unnecessary dose, resulting in excess cost. Selective vaccination has been proposed as one solution to this; children who were able to provide documentation of previous vaccination would not be vaccinated repeatedly. While this would result in reduced vaccine and supply cost, it would also require additional staff time and increased social mobilization investment, potentially outweighing the benefits. We utilize Monte Carlo simulation to assess under what conditions a selective vaccination policy would indeed result in net savings. We demonstrate that cost savings are possible in contexts with a high joint probability of an individual child having both 2+ previous measles doses and also an available record. We also find that the magnitude of net cost savings is highly dependent on whether a country is using measles-only or measles-rubella vaccine and on the required skill set of the individual who would review the previous vaccination records.

Identifiants

pubmed: 31471145
pii: S0264-410X(19)31113-2
doi: 10.1016/j.vaccine.2019.08.049
pii:
doi:

Substances chimiques

Measles Vaccine 0
Rubella Vaccine 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

6093-6101

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Brittany L Hagedorn (BL)

Institute for Disease Modeling, 3150 139th Ave SE, Bellevue, WA 98005, USA. Electronic address: bhagedorn@idmod.org.

Alya Dabbagh (A)

Department of Immunization, Vaccines, and Biologicals, World Health Organization, Avenue Appia 20, 1211 Genève, Switzerland.

Kevin A McCarthy (KA)

Institute for Disease Modeling, 3150 139th Ave SE, Bellevue, WA 98005, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH